Israel’s Kamada has been allowed a patent in Canada for the large-scale production of Alpha-1 Proteinase Inhibitor. The process is key to Kamada’s treatments for alpha-1 antitrypsin (AAT) deficient patients suffering from type-1 diabetes and pulmonary diseases, amongst others.
http://www.globes.co.il/en/article-kamada-receives-canadian-patent-1001025127